The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered in Vitro by Human Ovarian Cancer Cells IGROV1

Clinical and Applied Thrombosis/Hemostasis

Volumn 23, Issue 2, 2017, Pages 155-163

  Sassi, Mouna ^a,b   Chakroun, Taher ^a,c   Mbemba, Elisabeth ^a   Van Dreden, Patrick ^d   Elalamy, Ismail ^a,d,e   Larsen, Annette K ^a   Gerotziafas, Grigoris T ^a,d,e  

^a CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^b FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^c Ctr Regional de Transfus Sang   (Tunisia)

^d Clinical Research Department   (France)

^e ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

enoxaparin; hypercoagulability; ovarian cancer; thrombin generation; tinzaparin

Indexed keywords

ENOXAPARIN; PHOSPHOLIPID; PROCOAGULANT; THROMBIN; THROMBOPLASTIN; TINZAPARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; FACTOR IIA; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN;

ARTICLE; BLOOD ANALYSIS; CHEMOLUMINESCENCE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IC50; IMMUNOPRECIPITATION; IN VITRO STUDY; NONHUMAN; OVARIAN CANCER CELL LINE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBIN TIME; THROMBOCYTE POOR PLASMA; TISSUE CULTURE; VENOUS THROMBOEMBOLISM; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; PLASMA; TUMOR CELL LINE;

CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; FACTOR XA INHIBITORS; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; OVARIAN NEOPLASMS; PLASMA; PROTHROMBIN; THROMBIN; THROMBOPLASTIN;

EID: 85011664785     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029616665922     Document Type: Article

References (35)

1. Sallah S, Ahmad O, Kaiser HE,. Pathogenesis of thrombotic disorders in patients with cancer. In Vivo. 2000; 14 (1): 251-253.
2. Pabinger I, Ay C,. Risk of venous thromboembolism and primary prophylaxis in cancer. Should all patients receive thromboprophylaxis. ? Hamostaseologie. 2012; 32 (2): 132-137.
3. Noble S, Pasi J,. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer. 2010; 102 (suppl 1): S2-S9.
4. Khorana A,. Cancer and coagulation. Am J Hematol. 2012; 87 (suppl 1): S82-S87.
5. Iodice S, Gandini S, Lohr M, Lowenfels AB, Maisonneuve P,. Venous thromboembolic events and organ-specific occult cancers: a review and meta-analysis. J Thromb Haemost. 2008; 6 (5): 781-788.
6. Rickles FR,. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb. 2006; 35 (1-2): 103-110.
7. Ruf W, Yokota N, Schaffner F,. Tissue factor in cancer progression and angiogenesis. Thromb Res. 2010; 125 (suppl 2): S36-S38.
8. Hanna DL, White RH, Wun T,. Biomolecular markers of cancer-associated thromboembolism. Crit Rev Oncol Hematol. 2013; 88 (1): 19-29.
9. Hemker HC, Giesen P, Aldrieri R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb. 2002; 32: 249-253.
10. Hemker HC, Beguin S,. Phenotyping the clotting system. Thromb Haemost. 2000; 84 (5): 741-751.
11. Al Dieri R, Laat B, Hemker HC,. Thrombin generation: what have we learned? Blood Rev. 2012; 26 (5): 197-203.
12. Baglin T,. The measurement and application of thrombin generation. Br J Hematol. 2005; 130 (5): 653-661.
13. Chaari M, Ayadi I, Rousseau A, Lefkou E, et al. Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability. BMC Cancer. 2014; 14: 991.
14. Benyo M, Flasko T, Molnar Z, et al. Follow-up of thrombin generation after prostate cancer surgery: global test for increased hypercoagulability. PLoS One. 2012; 7 (12): e51299.
15. Thomas O, Lybeck E, Strandberg K, Tynngård N, Schött U,. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays. PLoS One. 2015; 10 (1): e0116835.
16. Gatt A, Van Veen JJ, Woolley AM, Kitchen S, Cooper P, Makris M,. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost. 2008; 100 (2): 350-355.
17. Greaves M, Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of anticoagulation Subcommittee of the Scientific and Standardization Committee of the international Society of Thrombosis and Haemostasis. Thromb Haemost. 2002; 87 (1): 163-164.
18. Castoldi E, Rosing J,. Thrombin generation tests. Thromb Res. 2011; 127 (suppl 3): S21-S25.
19. Akl EA, Vasireddi SR, Gunukula S, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2011; 6: CD006649.
20. Lyman GH,. Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. Cancer. 2009; 115 (24): 5637-5650.
21. Gerotziafas GT, Galea V, Mbemba E, et al. Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7. Thromb Res. 2012; 129 (6): 779-786.
22. Gerotziafas GT, Galea V, Mbemba E, et al. Effect of low molecular weight heparins and fondaparinux upon thrombin generation triggered by human pancreatic cancer cells BXPC3. Curr Vasc Pharmacol. 2014; 12 (6): 893-902.
23. Rousseau A, Van Dreden P, Mbemba E, Elalamy I, Larsen A, Gerotziafas GT,. Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin. Thromb Res. 2015; 136 (6): 1273-1279.
24. Marchetti M, Diani E, ten Cate H, Falanga A,. Characterization of the thrombin generation potential of leukemic and solid tumor cells by calibrated automated thrombography. Haematologica. 2012; 97 (8): 1173-1180.
25. Tateo S, Mereu L, Salamano S, et al. Ovarian cancer and venous thromboembolism risk. Gynecol oncol. 2005; 99 (1): 119-125.
26. Satoh T, Oki A, Uno K, et al. High incidence of silent venous thromboembolism before treatment in ovarian cancer. Br J Cancer. 2007; 97: 1053-1057.
27. Bénard J, Da silva J, De Blois MC, et al. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res. 1985; 45 (10): 4970-4979.
28. Davis A, Afshar-Khargha V, Sood AK,. Platelet effects on ovarian cancer. Semin Oncol. 2014; 41 (3): 378-384.
29. von Tempelhoff GF, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L,. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost. 1997; 77 (3): 456-461.
30. von Tempelhoff GF, Heilmann L, Hommel G, Schneider D, Niemann F, Zoller H,. Hyperviscosity syndrome in patients with ovarian carcinoma. Cancer. 1998; 82 (6): 1104-1111.
31. De Cicco M,. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol. 2004; 50 (3): 187-196.
32. Uno K, Homma S, Nakanishi K, Nakanishi K, Abe D, Matsumoto K, et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer. 2007; 96 (2): 290-295.
33. Gerotziafas GT, Petropoulou AD, Verdy E, Samama MM, Elalamy I,. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost. 2007; 5 (5): 955-962.
34. Gerotziafas GT, Depasse F, Busson J, Le Flem L, Elalamy I, Samama MM,. Towards a standardization of thrombin generation assessment: the influence of the tissue factor, platelets and phospholipids concentration on the normal value of Thrombogram-Thrombinoscope assay. Thromb J. 2005; 3: 16.
35. Debaugnies F, Azerad MA, Noubouossié D, et al. Evaluation of the procoagulant activity in the plasma of cancer patients using a thrombin generation assay. Thromb Res. 2010; 126 (6): 531-535.